School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou 450001, China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.
School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou 450001, China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.
Acta Biomater. 2016 Jul 1;38:129-42. doi: 10.1016/j.actbio.2016.04.024. Epub 2016 Apr 16.
In this work, a tumor-targeted and multi-stimuli responsive drug delivery system has been developed for combining photoacoustic tomography imaging with chemo-phototherapy. We utilized a kind of near infrared (NIR) resonant material-hollow mesoporous copper sulfide nanoparticles (HMCuS NPs) to encapsulate doxorubicin (DOX). After that, the outer surface of HMCuS NPs was capped with multifunctional hyaluronic acid (HA) simultaneously as smart gatekeeper as well as tumor targeting moiety. Herein, HMCuS-HA could serve as a powerful contrast agent for photoacoustic tomography (PAT) to guide chemo-phototherapy by providing the identification of cancerous lesions. In vitro and in vivo studies, the nanoplatform (DOX/HMCuS-HA) pinpointed MCF-7 cells via CD44 receptor-mediated endocytosis pathway. Subsequently, intracellular enzyme-responsive controlled drug release would take place in lysosome after the HA degradation by hyaluronidase. Under near infrared (NIR) light irradiation, HMCuS NPs could not only effectively convert NIR light into heat for photothermal therapy, but also generate high levels of reactive oxygen species (ROS) for photodynamic therapy. In addition, NIR light and low pH environment could facilitate intracellular tunable drug release with spatial/temporal resolution, and thus synergistic combination of chemo-phototherapy should be simultaneously driven by an 808nm laser irradiation, which brought out an outstanding therapeutic effect. In vivo optical imaging demonstrated that HMCuS-HA significantly enhanced targeting and accumulation capacity in tumor site. Furthermore, tumor-bearing mice treated with DOX/HMCuS-HA under NIR irradiation (808nm, 2W/cm(2), 0.5min) in vivo displayed the highest inhibition ratio of about 88.9%. Taken together, our present study of the tumor-targeted and multi-stimuli responsive drug delivery system provides new insights into multimodality theranostic applications in cancer treatment.
Until now, chemotherapy is still the major therapeutic approach applied in oncology. Despite their pharmacologically efficacy in cancer treatments, most chemotherapeutic agents without tumor-specific targeting ability have brought out serious toxicities to normal tissues. This study provides a promising near infrared (NIR) resonant material-hollow mesoporous copper sulfide nanoparticles (HMCuS NPs) with capping of multifunctional hyaluronic acid (HA) simultaneously as smart gatekeeper as well as tumor targeting moiety to address the above problem. After the nanoplatform (DOX/HMCuS-HA) pinpointed breast cancer cells via CD44 receptor-mediated endocytosis pathway, intracellular multi-stimuli responsive controlled drug release would take place with remarkable spatial/temporal resolution. Then photoacoustic tomography (PAT) and synergistic combination of chemo-phototherapy would be simultaneously driven by the same NIR irradiation in a coordinated way, which brought out an outstanding theranostic effect. This work can arouse broad interests among researchers in the fields of nanomedicine, nanotechnology, and drug delivery system.
本研究构建了一种用于联合光声断层扫描成像与化疗-光疗的肿瘤靶向、多刺激响应型药物递送系统。
我们利用一种近红外(NIR)共振材料-中空介孔硫化铜纳米颗粒(HMCuS NPs)包载阿霉素(DOX)。之后,HMCuS NPs 的外表面同时被多功能透明质酸(HA)覆盖,作为智能门控和肿瘤靶向部分。在此,HMCuS-HA 可作为光声断层扫描(PAT)的强大造影剂,通过提供癌症病变的识别来指导化疗-光疗。体外和体内研究表明,该纳米平台(DOX/HMCuS-HA)通过 CD44 受体介导的内吞途径靶向 MCF-7 细胞。随后,HA 被透明质酸酶降解后,细胞内的酶响应控制药物释放将在溶酶体中发生。在近红外(NIR)光照射下,HMCuS NPs 不仅能有效将 NIR 光转化为热量进行光热治疗,还能产生高水平的活性氧(ROS)进行光动力治疗。此外,NIR 光和低 pH 环境可以促进细胞内具有时空分辨率的可调药物释放,从而协同驱动 808nm 激光照射下的化疗-光疗,带来卓越的治疗效果。体内光学成像表明,HMCuS-HA 显著增强了在肿瘤部位的靶向和积累能力。此外,荷瘤小鼠经 NIR 照射(808nm,2W/cm(2),0.5min)体内治疗后,DOX/HMCuS-HA 的抑制率最高可达约 88.9%。
本研究构建的肿瘤靶向、多刺激响应型药物递送系统为癌症治疗的多模式治疗应用提供了新的思路。